JAGX JAGX
Company Profile ↓Company Overview
JAGX (JAGX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $11.51M (-1.5% YoY); net profit $-53.58M.
- Trailing 12 Months Year-on-year growth — revenue -1.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.17% |
| 1 Year: | -1.52% |
Stock Price Performance
| 1 Year: | -98.60% |
| 6 Months: | -95.02% |
| 3 Months: | -64.95% |
| 1 Month: | -60.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.25 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 98.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 896.52K | - | - | 883.85K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.95M | -1.94M | -2.58M | -2.68M | -3.17M | -2.75M | -3.68M | -3.41M | -3.18M | -3.88M | -2.35M | -7.34M | -5.13M | -7.08M | -6.51M | -5.78M | -10.62M | -6.73M | -7.65M | -8.45M | -5.38M | -8.77M | -11.58M | -9.53M | -11.75M | -6.48M | -9.90M | -9.85M | -8.10M | -8.79M | -8.21M | -7.20M | -7.26M | -9.42M | -8.01M | -7.24M | 10.18M |
| Net Income | -1.97M | -1.94M | -2.73M | -3.94M | -5.26M | -2.96M | -3.98M | -3.66M | -3.42M | -4.72M | -1.81M | 4.76M | -5.70M | -7.66M | -6.14M | -8.30M | -16.72M | -7.55M | -7.94M | -9.24M | -7.87M | -12.01M | -14.08M | -12.19M | -17.99M | -9.37M | -12.52M | -12.20M | -12.15M | -7.78M | -9.23M | -9.49M | -9.85M | -10.46M | -10.41M | -9.50M | - |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.30 | - | - | 1.11 | - | - | -0.51 | - | - | - | - | -0.44 | -0.62 | -0.28 | -0.31 | -0.27 | -23.10 | -8.77 | -8.83 | -2.39 | -41.35 | -22.50 | -87.12 | -2.66 | -26.29 | -584.45 | -10.26 | -6.28 | -13.60 |
| R&D Expense | 1.46M | 691.18K | 1.13M | 1.42M | 1.75M | 1.24M | 1.75M | 1.95M | 1.97M | 1.26M | 926.79K | 851.61K | 757.87K | 1.60M | 1.48M | 1.42M | 1.70M | 1.31M | 1.58M | 1.41M | 1.52M | 2.41M | 3.87M | 3.31M | 4.95M | 2.45M | 5.94M | 4.78M | 4.28M | 6.08M | 4.31M | 3.65M | 4.04M | 3.73M | 3.27M | 3.66M | 3.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 258.38K | 141.52K | 4.36M | 4.42M | 5.78M | 9.38M | 4.33M | 11.96M | 9.76M | 11.69M | 11.51M |
| Operating Income | -8.32M | -12.45M | -13.59M | -34.25M | -30.82M | -28.95M | -26.65M | -40.71M | -34.41M | -34.29M | -30.83M | -45.91M |
| Net Income | -8.61M | -16.29M | -14.73M | -21.97M | -32.15M | -38.54M | -33.81M | -52.59M | -47.45M | -41.30M | -38.49M | -53.58M |
| Diluted EPS | - | - | - | - | - | - | -3.00 | -88.22 | -36.18 | -2,678.17 | -130.69 | -22.97 |
| R&D Expense | 4.22M | 6.48M | 7.21M | 4.27M | 5.15M | 5.82M | 6.41M | 15.08M | 17.65M | 18.60M | 16.54M | 24.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.42M | 12.41M | 3.56M | 43.63M | 41.04M | 36.41M | 42.84M | 53.27M | 47.45M | 50.76M | 53.42M | 38.32M |
| Total Equity | -434.85K | -8.24M | 4.40M | -2.45M | 17.26M | 5.38M | 10.67M | 17.20M | 11.85M | -1.36M | 4.90M | 6.49M | -18.69M |
| Cash & Equivalents | 185.37K | 845.19K | 7.70M | 950.98K | 520.70K | 2.57M | 3.50M | 8.09M | 17.05M | 5.47M | 6.47M | 8.00M | 968.00K |
| Long Term Debt | - | - | 4.10M | 1.82M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 5.35M | 8.01M | 6.02M | 26.37M | 26.66M | 15.84M | 25.64M | 41.41M | 48.81M | 45.87M | 44.45M | 57.01M |
| Current Liabilities | - | 3.48M | 3.91M | 4.19M | 15.39M | 26.66M | 15.39M | 13.22M | 15.47M | 30.34M | 13.99M | 19.70M | 40.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -14.41M | -9.82M | -22.73M | -20.46M | -15.28M | -34.97M | -33.10M | -33.24M | -29.38M | -23.69M |
| Investing Cash Flow | - | - | 2.38M | -1.56M | -6.53K | - | -7.00K | -6.00K | -1.68M | - | -231.00K | -41.00K |
| Financing Cash Flow | - | - | 5.28M | 10.68M | 24.55M | 21.77M | 19.49M | 43.94M | 23.18M | 34.23M | 31.20M | 23.67M |
| Capital Expenditure | -55.15K | -23.30K | -104.21K | - | -6.53K | - | -7.00K | -6.00K | -77.00K | - | -16.00K | - |
| Free Cash Flow | - | - | -14.52M | - | -22.74M | - | -15.29M | -34.98M | -33.18M | - | -29.40M | - |
| Share Buybacks | - | - | - | - | 30 | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -4,816.7% | -9,599.8% | -785.3% | -698.0% | -501.3% | -283.9% | -939.1% | -287.8% | -351.3% | -263.8% | -398.8% |
| Net Margin % | - | -6,305.2% | -10,410.9% | -503.7% | -727.9% | -667.3% | -360.2% | -1,213.3% | -396.9% | -423.1% | -329.3% | -465.4% |
| ROE % | 104.5% | -370.3% | 600.4% | -127.3% | -597.2% | -361.1% | -196.5% | -443.7% | 3,491.8% | -843.4% | -592.7% | 286.7% |
| ROCE % | -880.3% | -146.5% | 2,157.5% | -121.3% | -214.3% | -137.7% | -90.0% | -107.7% | -201.1% | -93.2% | -91.4% | 1,969.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JAGX
After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNRnpwak5HZW5zYUUya200SlZzSUNhcktUcEQwQ3dzMGJtamd5Yi03a1lMYXVadDBwUWNEYlJkRURBRTdDWlZNTzd6VWw1d1hzYkEyZVlOTVc0em1kQkxkV2Jic2lPRnlSUUxXWnEzVTBRSEt6VTBwZmQ3SXdmenp0Tkc0aWk1UXZ3Z2JuUG…
Why is Jaguar Health stock gaining today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOV1RoTEw1ODF4elloSzZ0anNrbzJPSGdZMTRramhRTFBuQWVwLUpRY3haTHVwXzlTVXYtWDMxS2hVWmVSaFZadWFRTTVacGgzdEtaTUtCenowVFpxeERZVTVqYlZyY3lVS3JPWjlRMnZ5R1BPV0FOc3FvZHdUWE9fV0FFUzhRS19fYUw3VH…
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOVHoyUTVTR2FKb1l5VXZZX0Q4bThFRWVBYnBfNnFTX0ZnM0FUU1NsZ0ltYTBBWFc4SkpLS0JjM3l6dklYZ1NxTDkzSkZ2d3BwQURneWNYLUgzX3BLaE9HejEzanR4UTAtUzY4RTZXTEVTR1hPRnJsMXprb05RRFhqQTc0T0NNX3BXc190Qm…
JAGUAR HEALTH ($JAGX) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPUXhLcHBvLTZ3QVJLZGEtd1lXaE16SDB1aHVBTmU4YUFNUEZvTUttcmFmUExXNGVuTzZiNV9wRTRTZnZuc3p2YWh5dEZJbVlyV1lSNXNIVUNYanlNTXFzVmFndlFhWVYtQ0NYQWdnRjJzWkN0ZGwxdGhvY0pSNi0xN3I2MWFPM3FKcEFSZz…
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUEQzTXhLZEQ0eGdTRlV4X2lVS3ZxdzE3bEdUVXZHN293ZS1veUVHQnhVazFGWlRjbXNYVVdRUTFNNkx2eTI4M3BwM3JpcmFpOG1ZdmdqNFZ4N1J6a3FyN2h4TlJlLUllbEtlYnplNHluZ1pxV21LZmFueEtVeFRtUUVJa3A2amc4MHRBQz…
Jaguar Health Sets $40 Million ELOC and Closes $2 Million Series P Financing - TradingView
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNRWd1LWNWdjFwV2o3ZVZBTEw3WXhra0lHZWcwcFd4eFlNV3pHRXZyWmdRZkFZaGJyT3Fxb19uMldoTzZFSmZuakpHMDZoSHVlY3k2UjJ4NFM0aEVlRW1KbjdfWUF6YUhXcXR0ZTRLbkR1TVhKbU1NcGYySzBGb1o4RTZhbGU5M2VvSC13aV…
JAGX — Frequently Asked Questions
What is the current share price of JAGX?
As of 2026-08-05 17:25 PDT, JAGX trades at $1.06 on NASDAQ/NYSE. Its 52-week range is $0.96 to $90.65.
What is the P/E ratio of JAGX?
JAGX trades at a trailing price-to-earnings (P/E) ratio of -0.05.
Is JAGX a good stock to buy?
This page provides a data-driven analysis of JAGX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.